COMMUNIQUÉS West-GlobeNewswire

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
30/04/2025
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7
30/04/2025
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a [...]
Kestra Medical Technologies to Participate in Upcoming Investor Conferences
30/04/2025
KIRKLAND, Wash., April 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming [...]
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
30/04/2025
Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications and collaborations [...]
Commure’s AI-Powered Ambient Suite Achieves Epic Toolbox Designation for Ambient Voice Recognition
30/04/2025
Commure Ambient AI is now available in Toolbox on Epic Showroom, empowering healthcare organizations to streamline workflows, enhance care delivery, and overcome workforce challenges MOUNTAIN VIEW, Calif., April 30, [...]
Intercept Announces Data to be Presented at Digestive Disease Week 2025
30/04/2025
Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and bezafibrate in PBC, along with 10 other abstracts MORRISTOWN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- [...]
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
30/04/2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today [...]
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
30/04/2025
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans [...]
electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025
30/04/2025
ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended [...]
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
30/04/2025
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its [...]
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
30/04/2025
This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can reduce the risk of cancer recurrence and spread ATHENS, Greece and LOS ANGELES, April 30, [...]
Mountainside Joins Northwell Direct Network to Offer Best-in-Class Addiction Treatment
30/04/2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Mountainside Treatment Center is pleased to be named an in-network provider with Northwell Direct, owned by Northwell Health, New York State’s largest healthcare provider and [...]
DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
30/04/2025
Reconnu pour ses avancées dans le domaine des soins des plaies à l’échelle mondiale grâce à son caractère innovant et à son efficacité AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx [...]
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
30/04/2025
Recognized for Advancing Global Wound Care Through Innovation and Efficacy AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 [...]
Notice of Annual General Meeting 2025
30/04/2025
Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The notice and proposed [...]
Essential Pharma strengthens Board with the appointment of Jonathan Arnold as Non-Executive Director
30/04/2025
Essential Pharma strengthens Board with the appointment of Jonathan Arnold as Non-Executive Director Egham, UK – 30 April 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company [...]
RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®
30/04/2025
BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA ® , their co-developed innovative AI algorithm for [...]
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
30/04/2025
Oslo, Norway, 30 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites to a webcast presentation of [...]
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
30/04/2025
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable [...]

Pages